TY - JOUR
T1 - Prognosis of immune-related adverse events in patients with advanced gastric cancer treated with nivolumab or pembrolizumab
T2 - A multicenter retrospective analysis
AU - Ando, Takayuki
AU - Ueda, Akira
AU - Ogawa, Kohei
AU - Motoo, Iori
AU - Kajiura, Shinya
AU - Nakajima, Takahiko
AU - Hirano, Katsuhisa
AU - Okumura, Tomoyuki
AU - Tsukada, Kenichiro
AU - Hara, Takuo
AU - Suzuki, Nobuhiro
AU - Nakada, Naokatsu
AU - Horikawa, Naoki
AU - Fujii, Tsutomu
AU - Yasuda, Ichiro
N1 - Publisher Copyright:
© 2021 International Institute of Anticancer Research. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Background: Immune-checkpoint inhibitors (ICI), including nivolumab and pembrolizumab, are among the standard treatments for previously treated advanced gastric cancer (AGC). This study aimed to evaluate the frequency of immune-related adverse events (irAEs) and the correlation between irAEs and their efficacy in AGC cases. Patients and Methods: Patients were divided into two groups according to irAE occurrence. The frequency of irAEs and the treatment outcome (response rate [RR], progression-free survival [PFS], and overall survival [OS]) were evaluated. The survival rates were evaluated by landmark analysis considering lead-time bias. Results: Among 108 patients who received nivolumab or pembrolizumab, 17 (15.7%) had irAEs. In a 4-week landmark analysis, the RR, median PFS, and median OS were 28.5%, 3.9 months (95% CI=2.8-9.3), and 12.2 months (95% CI=3.8-NA) in patients with irAEs, while 3.0% (2/65), 1.8 months (95% CI=1.4-2.1), and 3.5 months (95% CI, 2.9-5.1) in patients without irAEs, respectively. In multivariate analysis, irAEs were associated with better PFS (HR=2.08, 95% CI=1.34-3.21). Conclusion: The occurrence of irAEs was associated with a better clinical outcome of ICIs in patients with AGC.
AB - Background: Immune-checkpoint inhibitors (ICI), including nivolumab and pembrolizumab, are among the standard treatments for previously treated advanced gastric cancer (AGC). This study aimed to evaluate the frequency of immune-related adverse events (irAEs) and the correlation between irAEs and their efficacy in AGC cases. Patients and Methods: Patients were divided into two groups according to irAE occurrence. The frequency of irAEs and the treatment outcome (response rate [RR], progression-free survival [PFS], and overall survival [OS]) were evaluated. The survival rates were evaluated by landmark analysis considering lead-time bias. Results: Among 108 patients who received nivolumab or pembrolizumab, 17 (15.7%) had irAEs. In a 4-week landmark analysis, the RR, median PFS, and median OS were 28.5%, 3.9 months (95% CI=2.8-9.3), and 12.2 months (95% CI=3.8-NA) in patients with irAEs, while 3.0% (2/65), 1.8 months (95% CI=1.4-2.1), and 3.5 months (95% CI, 2.9-5.1) in patients without irAEs, respectively. In multivariate analysis, irAEs were associated with better PFS (HR=2.08, 95% CI=1.34-3.21). Conclusion: The occurrence of irAEs was associated with a better clinical outcome of ICIs in patients with AGC.
KW - Immune-related adverse events
KW - Nivolumab
KW - Pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85099417818&partnerID=8YFLogxK
U2 - 10.21873/INVIVO.12281
DO - 10.21873/INVIVO.12281
M3 - 学術論文
C2 - 33402499
AN - SCOPUS:85099417818
SN - 0258-851X
VL - 35
SP - 475
EP - 482
JO - In Vivo
JF - In Vivo
IS - 1
ER -
